Epilepsy Center

Epilepsy Center a part of Epilepsy Center @ Lund University Hospital However, it is not clear what the role of these agents is in mechanisms of epileptogenesis.

Epilepsy is one of the most devastating neurological diseases affecting about 1% of the population of the western countries. Despite certain progress in antiepileptic drug development in about 30-40% of cases epileptic seizures do not respond to conventional pharmacological treatment therapies. Recently neuropeptides and neurotrophic factors emerged as strong regulators of excitatory and inhibitory synaptic transmission in the CNS thus offering a potent tool to counteract the seizure activity. We explore the role of neuropeptides and neurotrophic factors in modulation of excitatory and inhibitory synaptic transmission and epileptogensis in the brain. We use rats and trasngenic mice in combination with in vivo epilepsy models (kindling, status epilepsitcus) and in vitro approaches (patch-clamp in brain slices, optogenetics). One of the specific aims of this research line is to use both direct and indirect targeted gene transfer of neuropeptides and neurotrophic factors into the different brain regions to investigate mechanistic aspects of their action on synaptic transmission and epileptogensis. We also explore seizure-suppressant effects of optogenetic approach in vitro and in vivo in animal models of epilepsy. This research will help in better understanding of the mechanisms for epileptogenesis and might lead to development of new gene therapy-based strategies for epilepsy treatment.

10/08/2024

A new paper from Epilepsy Center has been published in *Experimental Neurology* highlighting the role of the extracellular matrix, particularly Collagen VI, in the regulation of network excitability in epilepsy. You can access the paper here: https://doi.org/10.1016/j.expneurol.2024.114911.

Key Highlights of the Paper:

Role of Collagen VI: The study demonstrates how Collagen VI modulates synaptic transmission, contributing to the regulation of neuronal excitability, which is crucial in understanding epilepsy mechanisms.

Potential Therapeutic Target: Findings suggest that targeting Collagen VI or its pathways could offer new avenues for developing treatments to control or prevent seizures.

Potential Biomarker: The research also highlights the potential of Collagen VI as a biomarker for epilepsy, which could be used to predict or monitor the disease's progression and response to treatment.

Comprehensive Analysis: The research combines molecular, cellular, and network-level analyses, providing a holistic view of how Collagen VI impacts brain excitability.

This research project has a long and storied history, beginning around 2008-2009 with my PhD student, Litsa Nikitidou. The project was later taken over by my postdoc, Alessandra Cifra, and subsequently by another postdoc, Tania Ramos. Over the years, many collaborators contributed significantly to this work, including groups funded by the EU Commission under the EPITARGET project at various stages. The final phase of the project was brought to completion by my PhD student, Esbjörn Melin.

Given its lengthy timeline, this project might just set a Guinness World Record for duration in neuroscience research! Joking aside, I want to extend my heartfelt thanks to everyone who contributed to this publication over the years. Your dedication and collaborative spirit have been essential to bringing this important work to fruition.

14/03/2024

Adress

Lund

Webbplats

Aviseringar

Var den första att veta och låt oss skicka ett mail när Epilepsy Center postar nyheter och kampanjer. Din e-postadress kommer inte att användas för något annat ändamål, och du kan när som helst avbryta prenumerationen.

Dela

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram